Professional Documents
Culture Documents
TARDIVE DYSKINESIA
Learning Objectives
Nonrhythmic Rhythmic
Non-
Suppressible
suppressible Dystonia Athetosis
Tics Chorea
Myoclonus
Drug-induced
•Levodopa-induced dyskinesia
•Antipsychotic-induced dyskinesia
•Dopamine receptor blocking agents (DRBAs)
• Involuntary choreoathetoid movements usually associated with lower facial and distal
extremity musculature (truncal movements also possible)
− Chorea: Quick, irregular, non-stereotype movements
− Athetosis: Slow, writhing, serpentine movements
• Not associated with direct sensory problems
• Of considerable clinical, medical, and legal concern because of potential persistence
despite drug discontinuation
Characteristic Distribution of TD
Dopamine Supersensitivity?
Blockade of D2 receptors in the nigrostriatal
dopamine pathway causes them to upregulate
= D2 antagonist
tardive dyskinesia
Stahl SM. Stahl's Essential Psychopharmacology. 4th ed. 2013; Lohr JB et al. CNS Drugs 2003;17:47-62.
Other Mechanism(s) of Drug-Induced TD
GSTM1
Cytochrome GSTP1 Oxidative stress-
P450 gene NQO1 related genes
NOS3
Vijayakumar D, Jankovic J. Drugs 2016;76(7):779-87; Aquino CC, Lang AE. Parkinsonism Related Disord 2014;20(suppl 1):S113-7.
Tardive Dyskinesia: Delayed Onset
Tardive Dyskinesia can occur in patients...
Exposure to DRBAs
During exposure
After 1 month of After 2 months
cumulative exposure to DRBAs
of withdrawal of
in older patients depot agent
Woerner et al. Am J Psychiatry 1998;155(11):1521-8; Correll CU et al. J Clin Psychiatry. 2017;78(8):1136-1147; Caroff SN et al.
Neurol Clin. 2011;29(1):127-48, viii; Miller et al. Schizophr Res 2005;80(1):33-43; Nasrallah. Ann Clin Psychiatry 2006;18(1):57-
62. ; Jeste et al. Arch Gen Psychiatry 1995;52(9):756-65; Jeste et al. Am J Psychiatry 2000;157(7):1150-5.
Tardive Dyskinesia Prevalence in
Second-Generation Antipsychotic Use
• TD prevalence higher in patients treated Mean TD Prevalence
with first-generation antipsychotics (FGAs) FGA SGA
• Recent meta-analysis comparison of TD Treatment Treatment
prevalence in FGAs versus second-
generation antipsychotics (SGAs) users 30.0% vs 20.7%
95% CI = 26.4%–33.8% 95% CI = 16.6%–25.4%
• However, SGAs still show risk of TD
TD rates significantly
−One-fifth of patients treated with lower with SGA
SGAs showed this “rare” side effect
treatment
41 Studies (N = 11,493)
Q = 9.17, P = 0.0024
Facial & 2. Lips and Perioral e.g. puckering, pouting, and smacking
Oral Area
Movements
3. Jaw e.g. biting, clenching, chewing, mouth opening, and
lateral
4. Tongue Rate only increase in movements both in and out of
mouth, NOT inability to sustain movement.
5. Upper (arms, wrists, Include choreic movements (rapid, objectively
hands, fingers) purposeless, irregular, spontaneous) and athetoid
Extremity movements (slow, irregular, complex, serpentine). DO
Movements NOT include tremor (repetitive, regular, rhythmic).
6. Lower (legs, knee, e.g. lateral knee movement, foot tapping, heel dropping,
ankles, toes) foot squirming, inversion and eversion of foot.
Trunk
7. Neck, shoulders, e.g. rocking, twisting, squirming, pelvic gyrations.
Movements Include diaphragmatic movements.
hips
Abnormal Involuntary Movement Scale (AIMS)
Instructions for Preforming Exam
1. Ask patient whether there is anything in his/her mouth (i.e., gum, candy, etc.) and if
there is, to remove it
2. Ask patient about the current condition of his/her teeth
• Ask patient if he/she wears dentures
• Do teeth or dentures bother patient now?
3. Ask patient whether he/she notices any movements in mouth, face, hands, or feet
• If yes, ask to describe and to what extent they currently bother patient or interfere with
his/her activities
4. Have the patient sit in chair with hands on knees, legs slightly apart, and feet flat on
floor
• Look at the entire body for movements while the patient is in this position
5. Ask the patient to sit with hands hanging unsupported
• If male, between his legs, if female and wearing a dress, hanging over her knees
• Observe hands and other body areas
6. Ask the patient to open his or her mouth
• Observe the tongue at rest within the mouth
• Do this twice.
Abnormal Involuntary Movement Scale (AIMS)
Instructions for Preforming Exam
7. Ask the patient to protrude his or her tongue
• Observe abnormalities of tongue movement
• Do this twice.
8. Ask the patient to tap his or her thumb with each finger as rapidly as possible for 10 to
15 seconds, first with right hand, then with left hand
• Observe facial and leg movements
9. Flex and extend the patient’s left and right arms, one at a time
10. Ask the patient to stand up
• Observe the patient in profile
• Observe all body areas again, hips included
11. Ask patient to extend both arms outstretched in front with palms down
• Observe trunk, legs, and mouth
12. Have patient walk a few paces, turn, and walk back to chair
• Observe hands and gait
• Do this twice
Impact on Quality of Life
Quality of life
Severity of TD
Vijayakumar D, Jankovic J. Drugs 2016;76(7):779-87.
Expected Course of Tardive Dyskinesia
80% Medication
discontinuation −Most report remission rates below
60% ~80% of patients 25%
• After discontinuation of the
40%
causing DRBAs, the rate of
20% remission is low
−Even with atypical antipsychotics,
0% reversibility rates remain low as
Time
only 20.5%5
1. Vinuela A et al. Tremor Other Hyperkinet Mov (N Y). 2014;4:282; 2. Fernandez HH et al. Neurology. 2001;56(6):805-7; 3. Glazer WM et al. Br J
Psychiatry. 1990;157:585-92; 4. Kang UJ et al. Mov Disord. 1986;1(3):193-208; 5. Zutshi D et al. Other Hyperkinet Mov (N Y). 2014;4:266.
Is Tardive Dyskinesia Preventable?
•Severe TD
-Switch to clozapine
psychosis
tardive
dyskinesia
Reserpine and Psychiatry
Pharmacological
properties
TBZ Reserpine
N
O
H
O
O O
Rapidly converted to
N dihydrotetrabenazine
N
O a, b enantiomers in a O
H ratio of 1:1 H
N N N N
O O O O
H H H H
OH OH OH OH
Yao et al. Eur J Med Chem 2011;46(5):1841-8; Kilbourn et al. Chirality 1997;9(1):59-62.
Valbenazine
• Designed to deliver metabolite in a controlled fashion
H H
N O
O O
O
O H
N
O
H
N
OH
Valbenazine (+)-𝜶-DHTBZ
Müller T. Expert Opinion Investig Drugs 2015;24(6):737-42; O'Brien et al. Movement Disord 2015;30(12):1681-7;
Skor H et al. Drugs R D. 2017; Epub ahead of print.
Valbenazine: Selective VMAT2 Inhibitor
Cumulative Proportion of Responders During 6-Week, Double-Blind, Phase II Trial
-0.5
-1.0
AIMS score (least squares [LS] mean
change from baseline to week 6, MMRM):
-1.5
-2.0 Valbenazine 40 mg -1.9 vs. -0.1 placebo;
p<0.05; effect size, d=0.52
-2.5
-3.0
Valbenazine 80 mg -3.2 vs. -0.1 placebo;
-3.5 p<0.001; effect size, d=0.90
-4.0
0 2 4 6
Time (weeks)
AIMS at week 6 for the valbenazine 80 mg dose was reduced 3.1 points more than placebo
(p<0.001)
Hauser RA et al. Am J Psychiatry. 2017;174(5):476-484.
Valbenazine
Safety and Tolerability
• PK profile permits once-daily dosing
• Psychiatric status remained stable
• Improved TD regardless of the use or type of concomitant AP
• Somnolence is the most common treatment-related AE
-Valbenazine (all doses), 10.9%; placebo, 4.2%
-May be due to depletion of monoamines in people with higher
plasma levels of valbenazine
O'Brien et al. Movement Disord 2015;30:1681-7; Hauser RA et al. Neurology 2016;86(16)(suppl PL02.003);
Hauser RA et al. Am J Psychiatry. 2017;174(5):476-484; Citrome L. Int J Clin Pract. 2017;e12964
Valbenazine Appears Safe and
Well-Tolerated Long-Term
• Data pooled from 3 long-term studies with valbenazine (up to 48
weeks) in adults with TD
• 66.5% of patients experienced treatment-emergent adverse events
(TEAEs), but only about 14.7% discontinued the drug due to AEs
Josiassen RC et al. Poster presented at: American Psychiatric Association (APA) 2017 Annual
Meeting; May 22, 2017; San Diego, CA.
Deutetrabenazine
• Deutetrabenazine is a selective VMAT2 inhibitor
• Deuteration is the replacing of hydrogen atoms with deuterium on a compound
O
- No change in shape, size, charge, or D3C
target pharmacology of small molecules N
D3C
O
- Chemical bond C-D is 8x stronger
H
- Prolongs half-life and improved PK
Deutetrabenazine
O
FDA Approved for Tardive Dyskinesia on August 30, 2017
- Initial dose 12 mg/day in two divided doses
- Titrate at weekly intervals by 6 mg/day based on reduction of tardive dyskinesia and tolerability
- Maximum recommended daily dosage of 48 mg (24 mg twice daily)
- No need to CYP2D6 genotyping
Fernandez HH et al. Neurology. 2017;88(21):2003-2010; Anderson et al. Poster presented at: American Psychiatric
Association Annual Meeting; May 2016; Atlanta, GA; NEI Prescribe App, 2017.
Pharmacokinetics of Deutetrabenazine
Mean Plasma Concentration
TOTAL alpha + beta (n=24-25)
70
30
20
10
0 6 12 18 24
* At Week 12
Mean Change in AIMS Score
-1 ** Placebo group
(n=59)
Decrease in mean AIMS:
-2 1.6 (SE=0.46)
Deutetrabenazine group
(n=58)
-3
Decrease in mean AIMS:
Placebo 3.0 (SE=0.45)
Deutetrabenazine
-4 p=0.019
Baseline 2 4 6 9 12
Weeks
AEs: somnolence, headache
AIMS: Abnormal Involuntary Movement Scale.
At Week 12
Least-squares mean change (points)
-1 Placebo group
mean AIMS: -1.4 points (SE=0.41)
-2
Deutetrabenazine 12 mg/d
mean AIMS: −2.1 points (SE 0.42)
*
Deutetrabenazine 24 mg/d
-3 ** mean AIMS: −3.2 points (SE 0.45)
**
40 44% • Treatment success was
35 defined as a rating of “much
30 improved” or “very much
25
26% 28% improved” on the CGIC
20
15
• Deutetrabenazine at doses of
10
24 mg/day and 36 mg/day
5
were efficacious and well
0 tolerated
Placebo Deutetrabenazine Deutetrabenazine Deutetrabenazine
(n=58) 12 mg/day 24 mg/day 36 mg/day
*p = 0.014
(n=60) (n=49) (n=55)
**p = 0.059
• Clonazepam
−Probably effective in decreasing TD symptoms short term
(approximately 3 months; efficacy wanes by 6 months)
• Amantadine
−Reduced TD when used conjointly with a neuroleptic during
the first 7 weeks (1 positive study; short-term use only)